Phio Pharmaceuticals has been granted a patent for RNAi constructs used in gene silencing. The constructs consist of a double stranded region connected to a single stranded region containing phosphorothioate modified nucleotides. The patent claims an isolated double stranded nucleic acid molecule with specific length and composition requirements. GlobalData’s report on Phio Pharmaceuticals gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Phio Pharmaceuticals, NSAID cancer drugs was a key innovation area identified from patents. Phio Pharmaceuticals's grant share as of June 2023 was 1%. Grant share is based on the ratio of number of grants to total number of patents.
Rnai constructs with phosphorothioate modified nucleotides for gene silencing
A recently granted patent (Publication Number: US11667915B2) describes an isolated double stranded nucleic acid molecule that can be used for inhibiting the expression of a target gene or treating diseases associated with the expression of the target gene. The molecule consists of a guide strand and a passenger strand, with the passenger strand being 8-18 nucleotides long and the guide strand being 16-28 nucleotides long. The double stranded nucleic acid molecule contains a double stranded region and a single stranded region, with the double stranded region being 8-18 nucleotides long and connected to the single stranded region through a cleavable chemical linker. The single stranded region comprises at least six phosphorothioate modified nucleotides.
The patent also mentions that the double stranded nucleic acid molecule can have additional properties, such as at least one 2' O methyl or 2' fluoro modification, or a lipophilic group. The single stranded region can occur at different ends of the passenger and guide strands, and can be DNA or RNA. The double stranded region can be a perfect duplex or contain at least one bulge region. The nucleic acid molecule can be chemically modified, with the chemical modification being 2' O methyl and/or 2' fluoro, and multiple chemical modifications can be present in the same molecule.
The patent further describes the use of the isolated double stranded nucleic acid molecule for inhibiting the expression of a target gene in mammalian cells. It also mentions a method for inducing RNA interference (RNAi) in a subject by administering the nucleic acid molecule. The method can be administered through various routes, such as systemic, intravenous, intraperitoneal, intradermal, topical, intranasal, inhalation, oral, intramucosal, local injection, subcutaneous, oral tracheal, or intraocular. The subject can be a human, and the target gene can be PPIB, MAP4K4, or SOD1.
In summary, the granted patent describes an isolated double stranded nucleic acid molecule that can be used for inhibiting the expression of a target gene or treating diseases associated with the expression of the target gene. The molecule has specific characteristics, such as the length of the guide and passenger strands, the presence of phosphorothioate modified nucleotides, and the potential for additional modifications. The patent also covers methods for using the nucleic acid molecule to inhibit gene expression and induce RNAi in mammalian cells, as well as compositions containing the molecule for treating diseases associated with the target gene.
To know more about GlobalData’s detailed insights on Phio Pharmaceuticals, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
